Biogen, Dyax ink $84M IP deal

Biogen has expanded its IP agreement with Dyax to include the discovery of additional antibody products identified using Dyax's proprietary drug discovery technology, phage display. Under the new agreement Dyax will provide at least ten additional product licenses to Biogen Idec. Dyax also granted Biogen a non-exclusive license to its antibody libraries and will conduct antibody discovery for the next three years. Biogen will give Dyax a $5 million upfront fee and guaranteed research funding. The deals could total $85 million in development and sales milestones as well as royalties for each antibody product commercialized by Biogen Idec using Dyax's technology.

Biogen previously used Dyax's phage display technology to develop BIIB-022, which is currently in Phase I trials for oncology, and additional preclinical multiple sclerosis targets.

- here's Dyax's release
- read the report for more